NCT04967521View on ClinicalTrials.gov

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced Dedifferentiated Liposarcoma
Interventions
DRUG

Abemaciclib

Abemaciclib will be administered 200mg orally twice a day. Each cycle is 28 days.

DRUG

Placebo

Placebo will be administered orally twice a day. Each cycle is 28 days.

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

27710

Duke University, Durham

32224

Mayo Clinic Florida, Jacksonville

60611

Northwestern University, Chicago

63129

Washington University School of Medicine, St Louis

80045

University of Colorado Cancer Center, Anschutz Medical Campus, Aurora

97239

Oregon Health & Science University, Portland

98109

University of Washington, Seattle

02114

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Sarcoma Alliance for Research through Collaboration

OTHER